Skip to main content
    B

    Boston Scientific Corp (BSX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $43.05
    -0.64 (-1.48%)

    Market Cap: $63.33B

    Last updated: Nov 17, 2026 at 4:39 PM ET

    Boston Scientific Corp (BSX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Boston Scientific (BSX) has a market cap of $63.33B and an enterprise value of $74.67B. Its trailing P/E of 13.5x is below its 10-year median of 27.1x. Its share count is down 2.23% from a year earlier.

    Total Valuation

    Enterprise value is 17.91% above the market cap, as debt exceeds cash.

    Market Cap$63.33B
    Enterprise Value$74.67B
    Latest price (Nov 17, 2026)$43.05

    Key Dates

    The next earnings report is expected on Feb 2, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 2, 2027 (expected)
    Last Earnings DateOct 28, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 1.46% in the quarter ended Sep 30, 2026 and shrank 0.82% a year over 2 years.

    Shares Outstanding1.45B
    Shares Change (YoY)-2.23%
    Shares Change (QoQ)-1.46%
    Share Count Growth (2Y CAGR)-0.82%

    Valuation Ratios

    Sales and book value multiples are 3.0x and 2.4x. Its year-end P/E ranged from 19.3x to 37.4x from 2016 to 2025.

    P/E Ratio13.5x
    Forward P/E13.5x
    P/S Ratio3.0x
    Forward P/S3.0x
    P/B Ratio2.4x
    P/FCF Ratio18.7x
    P/OCF Ratio15.0x
    PEG Ratio1.6

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 13.5x EBITDA and 22.1x free cash flow.

    EV / Earnings21.4x
    EV / Sales3.5x
    EV / EBITDA13.5x
    EV / EBIT18.5x
    EV / FCF22.1x

    Price Statistics

    The stock is down 58.08% over 52 weeks and trades 1.91% below its 50-day average.

    Beta (1Y)0.27
    52-Week Change-58.08%
    1-Month Change-4.45%
    3-Month Change-17.24%
    6-Month Change-24.23%
    5-Year Change-2.67%
    10-Year Change+90.82%
    Total Return (1Y)-58.08%
    Total Return (3Y CAGR)-7.47%
    Total Return (5Y CAGR)+0.88%
    Return vs SPY (1Y)-68.18%
    Max Drawdown (1Y)-59.14%
    Max Drawdown (3Y)-61.55%
    Sharpe Ratio (1Y)-2.04
    Correlation with SPY (1Y)0.09
    50-Day Average$43.89
    200-Day Average$53.65
    52-Week Range$39.57 to $101.91
    RSI (14 Days)45.3
    Average Volume (20 Days)20.03M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.36x current liabilities, and total debt is 0.47x shareholder equity.

    Current Ratio1.36x
    Quick Ratio0.81x
    Debt / Equity0.47x
    Debt / EBITDA2.18x
    Debt / FCF3.59x
    Interest Coverage10.72x

    Returns and Efficiency

    Return on invested capital is 10.24% over the last 12 months, against a 5-year average of 6.20%.

    Return on Equity (ROE)13.63%
    Return on Assets (ROA)7.69%
    Return on Invested Capital (ROIC)10.24%
    Return on Capital Employed (ROCE)10.21%
    ROE (5Y Average)7.78%
    ROA (5Y Average)4.24%
    ROIC (5Y Average)6.20%
    Asset Turnover0.48x
    Inventory Turnover1.98x

    Taxes

    Income tax took 4.46% of pretax income over the last 12 months.

    Income Tax (TTM)$163.00M
    Effective Tax Rate4.46%

    Scores

    BSX has an Altman Z-Score of 2.98, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.

    Altman Z-Score2.98
    Altman Z ZoneGrey
    Piotroski F-Score7 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $21.07B over the last 12 months is up 8.87% from the 12 months before.

    Revenue$21.07B
    Revenue Growth (YoY)+8.87%
    Gross Profit$14.57B
    Operating Income$3.93B
    Pretax Income$3.65B
    Net Income$3.49B
    EBITDA$5.47B
    EBIT$4.03B
    Reported EPS (TTM)$3.19

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 56.38% of the $45.46B in total assets.

    Cash and Equivalents$609.00M
    Total Debt$11.95B
    Net Debt$11.34B
    Net Debt Per Share$7.83
    Working Capital$2.18B
    Shareholder Equity$25.63B
    Book Value Per Share$17.69
    Tangible Book Value$34.00M
    Tangible Book Per Share$0.02
    Total Assets$45.46B
    Total Liabilities$19.59B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $903.00M of capital spending, operating cash flow left $3.33B of free cash flow.

    Operating Cash Flow$4.23B
    Capital Expenditures$903.00M
    Free Cash Flow$3.33B
    FCF Per Share$2.30
    Depreciation and Amortization$1.45B

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 18.66%, against a 5-year average of 14.62%.

    Gross Margin69.15%
    Operating Margin18.66%
    Pretax Margin17.35%
    Net Margin16.58%
    EBITDA Margin25.98%
    EBIT Margin19.12%
    FCF Margin15.81%
    Gross Margin (5Y Average)68.94%
    Operating Margin (5Y Average)14.62%
    Net Margin (5Y Average)10.17%

    Growth

    Revenue grew 16.54% a year over 3 years, and EPS 21.27% a year.

    Revenue Growth (3Y CAGR)+16.54%
    Revenue Growth (5Y CAGR)+15.16%
    EPS Growth (3Y CAGR)+21.27%
    EPS Growth (5Y CAGR)+26.01%
    FCF Growth (3Y CAGR)+57.40%
    FCF Growth (5Y CAGR)+26.44%
    Operating Income Growth (3Y CAGR)+29.88%
    Book Value Per Share Growth (2Y CAGR)+11.39%

    Revenue and profit by year

    Dividends and Yields

    BSX does not pay a dividend. Its free cash flow yield is 5.34%.

    Earnings Yield7.41%
    FCF Yield5.34%
    Buyback Yield-0.32%
    Shareholder Yield-0.32%

    Stock Splits

    The last split was a 2-for-1 forward split on Nov 6, 2003.

    Last Split DateNov 6, 2003
    Split TypeForward split
    Split Ratio2:1

    Peer Position

    Against 10 similar companies, BSX has the 10th highest P/E.

    P/E Ratio13.5x vs 20.9x median
    P/S Ratio3.0x vs 3.6x median
    ROIC10.24% vs 7.46% median
    Revenue Growth (Trailing 4 Quarters, YoY)+8.87% vs +8.95% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 1.98% and EPS growth at 1.31% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+1.98%
    EPS Growth Forecast (2Y CAGR)+1.31%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About BSX

    What is BSX's market cap?

    Boston Scientific has a market cap of $63.33B. Its enterprise value, which adds debt and subtracts cash, is $74.67B.

    What is BSX's P/E ratio?

    Boston Scientific has a trailing P/E ratio of 13.5x and a forward P/E of 13.5x.

    How many shares of BSX are outstanding?

    Boston Scientific has 1.45B shares outstanding. The count is down 2.23% from a year earlier.

    Does BSX pay a dividend?

    No. Boston Scientific does not pay a dividend.

    How much debt does BSX have?

    Boston Scientific has $11.95B of total debt and $609.00M of cash and equivalents, a net debt position of $11.34B.